Tweed, CD; Wills, GH; Crook, AM; Amukoye, E; Balanag, V; Ban, AYL; Bateson, ALC; Betteridge, MC; Brumskine, W; Caoili, J; Chaisson, RE; Cevik, M; Conradie, F; Dawson, R; Del Parigi, A; Diacon, A; Everitt, DE; Fabiane, SM; Hunt, R; Ismail, AI; Lalloo, U; Lombard, L; Louw, C; Malahleha, M; McHugh, TD; Mende, CM; Mhimbira, F; Moodliar, RN; Ndub, V; Nunn, AJ; Sabi, I; Sebe, MA; Selepe, RAP; StapleS, S; Swindells, S; van Niekerk, CH; Variava, E; Spigelman, M; Gillespie, SH
(international journal of tuberculosis and lung disease, 2021-04)
BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed.METHODS: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin ...